• Delicious
  • Digg
  • Facebook
  • Twitter
  • Linkedin

Twitter updates

No public Twitter messages.

Popular Posts

Fortune telling in n

There are numerous individuals that trust that the future can ...

Important Ways to Ke

Similar to a cars and truck, a little upkeep will ...

Consummate program f

Locksmith administrations are common where wellbeing and security could be ...

Free Jackson skates

Succeeding to investing a month attempting feline skate, a skate ...

Taking the stress fr

Most of us understand that cycling is a terrific approach ...

meditation audio

Advantages of Medita

Life is brimming with bedlam and bother. In this, individuals ...


  • Reliable web hosting from WebHostingHub.com.
  • Domain name search and availability check by PCNames.com.
  • Website and logo design contests at DesignContest.net.
  • Reviews of the best cheap web hosting providers at WebHostingRating.com.

SARM or else known as Selective Androgen Receptor Modulator fall under the class of androgen receptor ligands and function by working on only selected androgen receptors. Their effect is similar to that of androgenic drugs but are more selective and limited in action and have taken over the anabolic steroids because they are used in more ways than the restricted legal use of the latter.


The Ongoing Research To Beat Osteoporosis With SARM

Despite the fact that SARM are widely used around the world, there are still certain compounds that are under preclinical trials to undermine various effects and actions of SARM to deduce potential clinical indications. One such research is to use selective androgen receptor modulator to treat osteoporosis in osteopenic female mice. The research concludes the additive effect of  a novel SARM on the action of bisphosphonate drug (a class of drug that reduces the loss of bone density thereby acting to treat osteoporosis)

The research involved the use of combination therapy involving lgd3033 (novel SARM) and alendronate (drug belonging to the class of bisphosphonate used to treat osteoporosis) which showed that the former component of the therapy was responsible for increasing both muscle weight and bone mineral density (BMD) and bone mineral content (BMC) at two bone sites; cortical and cancellous. The reason why alendronate was unable to achieve these results alone is because the novel SARM used in the combination therapy was responsible for their anabolic effect on the cortical bones and muscles.

The research will prove to be a breakthrough in the treatment of osteoporosis to an extent which is not approached by the existing potential drugs such as bisphosphonates. Furthermore, it will also expose the potential of the novel SARM used in the therapy as a potent single agent drug to treat the disease as its efficacy in a combination regimen is already determined.

Share This:

Comments are closed.